Cel­gene, Ac­celeron sub­mit FDA ap­pli­ca­tion for billed block­buster lus­pa­ter­cept — will they get pri­or­i­ty re­view?

Cel­gene and their part­ners at Ac­celeron are count­ing on their red blood cell boost­ing drug to win a speedy re­view as they sub­mit­ted a mar­ket­ing ap­pli­ca­tion for the bi­o­log­ic on Fri­day. For the big biotech — tar­nished by a poor per­for­mance un­der CEO Mark Alles — the drug is one of the top five in its pipeline, crit­i­cal for the mighty $74 bil­lion Bris­tol-My­ers Squibb takeover.

The drug, lus­pa­ter­cept, has been de­vel­oped to man­age ane­mia re­sult­ing from myelodys­plas­tic syn­drome (MDS) as well as be­ta tha­lassemia and has in­spired peak sales es­ti­mates of $2 bil­lion plus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.